Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients.

Creative Commons License

Cakirca M., Karatoprak C., Zorlu M., Kiskac M., Kanat M., CIKRIKCIOGLU M. A., ...More

Drug design, development and therapy, vol.8, pp.239-43, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 8
  • Publication Date: 2014
  • Doi Number: 10.2147/dddt.s52545
  • Journal Name: Drug design, development and therapy
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.239-43
  • Keywords: asymmetric dimethylarginine (ADMA), dipeptidyl peptidase-4 (DPP-4) inhibitor, vildagliptin, type 2 diabetes mellitus, GLUCAGON-LIKE PEPTIDE-1, MYOCARDIAL-INFARCTION, HEART-FAILURE, DYSFUNCTION, INHIBITION, RATS
  • Bezmialem Vakıf University Affiliated: Yes


Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.